Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate for adult patients with human immunodeficiency virus-1 in China: a retrospective real-world cohort study
CONCLUSION: This real-world cohort study showed that BIC/FTC/TAF could achieve good immunological and virological responses in ART-naïve patients. In addition, this study also shows good safety.PMID:38058002 | DOI:10.1080/14787210.2023.2292544
Source: Expert Review of Anti-Infective Therapy - Category: Infectious Diseases Authors: Lin Gan Xiaoxin Xie Yanhua Fu Yebing Song Chunli Song Tingting Ren Hai Long Source Type: research
More News: Allergy & Immunology | China Health | Infectious Diseases | Study | Truvada | Viread | Virology